Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

類似資料

• Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study
  著者:: Taher, Ali, 等
  出版事項: (2011)
• Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
  著者:: Daar, Shahina, 等
  出版事項: (2009)
• Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
  著者:: Taher, Ali, 等
  出版事項: (2011)
• Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration
  著者:: St Pierre, Tim G, 等
  出版事項: (2014)
• Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
  著者:: Pathare, Anil, 等
  出版事項: (2009)